

ABSTRACT

The present invention provides a crystal of a pharmaceutically acceptable salt of

5 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea. This crystal of salt is usable for the therapy of a disease selected from the group consisting of tumors, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, Kaposi's sarcoma, and exudation type

10 age-related maculopathy, and has characteristics suitable for applications of oral pharmaceutical preparations.